Correction: Descriptive Analysis for the Trend of Pharmacovigilance Planning in Risk Management Plans on New Drugs Approved During 2016-2019.

Kohama, Mei; Nonaka, Takahiro; Uyama, Yoshiaki; Ishiguro, Chieko

Kohama, Mei; Nonaka, Takahiro; Uyama, Yoshiaki; Ishiguro, Chieko.

Afiliación

Kohama M; Office of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
Nonaka T; Office of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
Uyama Y; Office of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
Ishiguro C; Section of Clinical Epidemiology, Department of Data Science, Center for Clinical Science, National Center for Global Health and Medicine, 1-21-1, Toyama Shinjuku-ku, Tokyo, 162-8655, Japan. chishiguro@hosp.ncgm.go.jp.

Ther Innov Regul Sci ; 57(1): 48, 2023 Jan.

Article en En | MEDLINE | ID: mdl-36008628

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Risk_factors_studies Idioma: En Revista: Ther Innov Regul Sci Año: 2023 Tipo del documento: Article País de afiliación: Japón

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google